Reply
Sir, Dr Farinati and colleagues have reported an uncontrolled experience with megestrol in the treatment of inoperable hepatocellular carcinoma. Their results were somewhat different from those we have reported in Br J Cancer ) and we would like to add some considerations.
Despite the fact that megestrol has a rationale in HCC characterised by both wild-type and variant oestrogen receptors (vERs), as its action is displayed at post-receptorial level (and therefore able to interfere both vERs and wild-type ERs (wtERs), still the natural history of HCC with wtERs is so favourable and the growth speed of the tumours so slow that megestrol or any other antihormonal drug, would not add much in terms of amelioration of prognosis (Villa et al, 2000) . The choice of treating with megestrol only patients with vERs was therefore justified by the much more aggressive clinical course of these HCCs, which could allow easier identification of any effect on tumour growth or an improvement in survival. As variant ERs are usually not more than 30% of patients with HCC, the higher percentage of patients with wildtype ERs could obscure a favourable effect of megestrol when this treatment is used in a mixed population.
Furthermore, the uncontrolled design of the study by Farinati et al, could not allow perception of the most relevant finding of our study, i.e. the improvement in survival in treated patients. It was, in fact, already evident from our data that megestrol did not determine regression of tumour mass (except in a few cases) whereas slowing down of tumour growth was remarkable in comparison with untreated patients. This effect was short-lived but sufficient to determine a significant improvement of survival at 1 year . Certainly, megestrol was not powerful enough to cure HCC, but in these patients with ominous prognosis, a gain of 10-12 months in survival can be considered an achievement. In a few of them, clinical improvement was also accompanied by significant regression of tumour mass which allowed performance of radical treatment (E Villa and V Mazzaferro, personal communication).
Last but not least, the side effects reported by Farinati et al (e.g. portal vein thrombosis, deep vein thrombosis, bleeding etc.) may also spontaneously occur in HCC patients: again the uncontrolled experimental design by Farinati was certainly not suitable for correctly allocating side effects to therapy or to disease. Indeed, in our series increase in appetite and in weight occurred in a remarkable percentage of treated patients and in none of the control. However, as for the vascular complications, deep vein thrombosis occurred in the same proportion in treated and untreated patients.
In conclusion, these considerations underline the need to observe very strict methodological rules when performing therapeutic trials: only a controlled method allows identification and correct allocation of both benefits and side effects.
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